The LUME-Lung Phase III programme for Nintedanib comprises two multinational trials. These placebo-controlled studies are investigating the safety and efficacy of Nintedanib in NSCLC patients after first line chemotherapy treatment. In the LUME-Lung 1 trial, which includes patients with all histologies, Nintedanib is administered in combination.
